PDMR Options Revision
Exercise price of CEO and CFO options granted in March 2025 increased from £0.13125 to £0.24 per share.
Select text to share a quote on X · sign in to keep highlights & notes in your CREO notes
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that, following consultation with a number of significant shareholders, the Group's Board has undertaken to change the exercise price of options granted to certain PDMRs on 24 March 2025.
Accordingly, the Company has agreed with each of Craig Gulliford, CEO, and Richard Rees, CFO, that the exercise price in respect of the options granted to each of them on 24 March 2025 is increased from £0.13125 to £0.24 per share. All other terms of the Options remain the same.
This announcement has been approved for release by the Board of Creo Medical Group plc.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.